OBJECTIVES: To determine whether a higher blood transfusion threshold would prevent new or worsening delirium symptoms in the hospital after hip fracture surgery. DESIGN: Ancillary study to a randomized clinical trial. SETTING:Thirteen hospitals in the United States and Canada. PARTICIPANTS: One hundred thirty-nine individuals hospitalized with hip fracture aged 50 and older (mean age 81.5 ± 9.1) with cardiovascular disease or risk factors and hemoglobin concentrations of less than 10 g/dL within 3 days of surgery recruited in an ancillary study of the Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair. INTERVENTION: Individuals in the liberal treatment group received one unit of packed red blood cells and as much blood as needed to maintain hemoglobin concentrations at greater than 10 g/dL; those in the restrictive treatment group received transfusions if they developed symptoms of anemia or their hemoglobin fell below 8 g/dL. MEASUREMENTS: Delirium assessments were performed before randomization and up to three times after randomization. The primary outcome was severity of delirium according to the Memorial Delirium Assessment Scale (MDAS). The secondary outcome was the presence or absence of delirium defined according to the Confusion Assessment Method (CAM). RESULTS: The liberal group received a median two units of blood and the restrictive group zero units of blood. Hemoglobin concentration on Day 1 after randomization was 1.4 g/dL higher in the liberal group. Treatment groups did not differ significantly at any time point or over time on MDAS delirium severity (P = .28) or CAM delirium presence (P = .83). CONCLUSION:Blood transfusion to maintain hemoglobin concentrations greater than 10 g/dL alone is unlikely to influence delirium severity or rate in individuals with hip fracture after surgery with a hemoglobin concentration less than 10 g/dL.
RCT Entities:
OBJECTIVES: To determine whether a higher blood transfusion threshold would prevent new or worsening delirium symptoms in the hospital after hip fracture surgery. DESIGN: Ancillary study to a randomized clinical trial. SETTING: Thirteen hospitals in the United States and Canada. PARTICIPANTS: One hundred thirty-nine individuals hospitalized with hip fracture aged 50 and older (mean age 81.5 ± 9.1) with cardiovascular disease or risk factors and hemoglobin concentrations of less than 10 g/dL within 3 days of surgery recruited in an ancillary study of the Transfusion Trigger Trial for Functional Outcomes in CardiovascularPatients Undergoing Surgical Hip Fracture Repair. INTERVENTION: Individuals in the liberal treatment group received one unit of packed red blood cells and as much blood as needed to maintain hemoglobin concentrations at greater than 10 g/dL; those in the restrictive treatment group received transfusions if they developed symptoms of anemia or their hemoglobin fell below 8 g/dL. MEASUREMENTS: Delirium assessments were performed before randomization and up to three times after randomization. The primary outcome was severity of delirium according to the Memorial Delirium Assessment Scale (MDAS). The secondary outcome was the presence or absence of delirium defined according to the Confusion Assessment Method (CAM). RESULTS: The liberal group received a median two units of blood and the restrictive group zero units of blood. Hemoglobin concentration on Day 1 after randomization was 1.4 g/dL higher in the liberal group. Treatment groups did not differ significantly at any time point or over time on MDAS delirium severity (P = .28) or CAM delirium presence (P = .83). CONCLUSION: Blood transfusion to maintain hemoglobin concentrations greater than 10 g/dL alone is unlikely to influence delirium severity or rate in individuals with hip fracture after surgery with a hemoglobin concentration less than 10 g/dL.
Authors: M S Albert; S E Levkoff; C Reilly; B Liptzin; D Pilgrim; P D Cleary; D Evans; J W Rowe Journal: J Geriatr Psychiatry Neurol Date: 1992 Jan-Mar Impact factor: 2.680
Authors: J L Carson; A Duff; J A Berlin; V A Lawrence; R M Poses; E C Huber; D A O'Hara; H Noveck; B L Strom Journal: JAMA Date: 1998-01-21 Impact factor: 56.272
Authors: J L Carson; M L Terrin; F B Barton; R Aaron; A G Greenburg; D A Heck; J Magaziner; F E Merlino; G Bunce; B McClelland; A Duff; H Noveck Journal: Transfusion Date: 1998-06 Impact factor: 3.157
Authors: Jennifer S Albrecht; Edward R Marcantonio; Darren M Roffey; Denise Orwig; Jay Magaziner; Michael Terrin; Jeffrey L Carson; Erik Barr; Jessica P Brown; Emma G Gentry; Ann L Gruber-Baldini Journal: J Am Geriatr Soc Date: 2015-05-04 Impact factor: 5.562
Authors: Tianjing Li; L Susan Wieland; Esther Oh; Karin J Neufeld; Nae-Yuh Wang; Kay Dickersin; Frederick E Sieber Journal: Clin Trials Date: 2017-01-09 Impact factor: 2.486
Authors: Sarah J Hemauer; Adam J Kingeter; Xue Han; Matthew S Shotwell; Pratik P Pandharipande; Liza M Weavind Journal: Crit Care Med Date: 2017-05 Impact factor: 7.598
Authors: Jeffrey L Carson; Simon J Stanworth; Jane A Dennis; Marialena Trivella; Nareg Roubinian; Dean A Fergusson; Darrell Triulzi; Carolyn Dorée; Paul C Hébert Journal: Cochrane Database Syst Rev Date: 2021-12-21
Authors: Jennifer K Burton; Louise Craig; Shun Qi Yong; Najma Siddiqi; Elizabeth A Teale; Rebecca Woodhouse; Amanda J Barugh; Alison M Shepherd; Alan Brunton; Suzanne C Freeman; Alex J Sutton; Terry J Quinn Journal: Cochrane Database Syst Rev Date: 2021-11-26
Authors: Jeffrey L Carson; Simon J Stanworth; Nareg Roubinian; Dean A Fergusson; Darrell Triulzi; Carolyn Doree; Paul C Hebert Journal: Cochrane Database Syst Rev Date: 2016-10-12
Authors: Jennifer K Burton; Louise E Craig; Shun Qi Yong; Najma Siddiqi; Elizabeth A Teale; Rebecca Woodhouse; Amanda J Barugh; Alison M Shepherd; Alan Brunton; Suzanne C Freeman; Alex J Sutton; Terry J Quinn Journal: Cochrane Database Syst Rev Date: 2021-07-19